BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22963812)

  • 1. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.
    Gresele P; Migliacci R; Procacci A; De Monte P; Bonizzoni E
    Thromb Haemost; 2007 Mar; 97(3):444-50. PubMed ID: 17334512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid foot and calf compression increases walking distance in patients with intermittent claudication: results of a randomized study.
    Ramaswami G; D'Ayala M; Hollier LH; Deutsch R; McElhinney AJ
    J Vasc Surg; 2005 May; 41(5):794-801. PubMed ID: 15886663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
    Messa GL; Gelso E
    Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
    Violi F; Marubini E; Coccheri S; Nenci GG
    Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm.
    Wilson AM; Harada R; Nair N; Balasubramanian N; Cooke JP
    Circulation; 2007 Jul; 116(2):188-95. PubMed ID: 17592080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
    Delis KT; Nicolaides AN; Wolfe JH; Stansby G
    J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
    Mohler ER; Hiatt WR; Creager MA
    Circulation; 2003 Sep; 108(12):1481-6. PubMed ID: 12952839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PoleStriding exercise and vitamin E for management of peripheral vascular disease.
    Collins EG; Edwin Langbein W; Orebaugh C; Bammert C; Hanson K; Reda D; Edwards LC; Littooy FN
    Med Sci Sports Exerc; 2003 Mar; 35(3):384-93. PubMed ID: 12618567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
    Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
    J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of supervised exercise to evaluate changes in cardiac function in patients with peripheral atherosclerotic disease.
    Hodges LD; Sandercock GR; Das SK; Brodie DA
    Clin Physiol Funct Imaging; 2008 Jan; 28(1):32-7. PubMed ID: 18005078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
    Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
    Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study.
    Gresele P; Migliacci R; Di Sante G; Nenci GG;
    Vasc Med; 2000; 5(2):83-9. PubMed ID: 10943584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication.
    de Haro J; Acin F; Florez A; Bleda S; Fernandez JL
    J Vasc Surg; 2010 Apr; 51(4):857-62. PubMed ID: 20347681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
    Creager MA; Olin JW; Belch JJ; Moneta GL; Henry TD; Rajagopalan S; Annex BH; Hiatt WR
    Circulation; 2011 Oct; 124(16):1765-73. PubMed ID: 21947297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication.
    Diehm C; Pittrow D; Lawall H
    J Hypertens; 2011 Jul; 29(7):1448-56. PubMed ID: 21602713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.